Navigation Links
Coronado Biosciences Reports Third Quarter 2011 Financial Results
Date:11/15/2011

Corporate presentationAbout Coronado BiosciencesCoronado Biosciences is engaged in the development of novel immunotherapy biologic agents.  The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML) and solid tumors.  For more information, please visit www.coronadobiosciences.com.  

Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Such statements include, but are not limited to, any statements relating to the Company's product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings.  We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any chang
'/>"/>

SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
2. Coronado Biosciences to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Coronado Biosciences Files to Become a Public Reporting Company
4. Coronado Biosciences Closes $25.8M in Series C Financing
5. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
6. Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
7. Signum Biosciences, Inc. Announces Collaborative Agreement with GlaxoSmithKline
8. Neurocrine Biosciences to Present at the 2011 Credit Suisse Annual Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results
10. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
11. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... COTTAGE, New York , July 30, 2015 /PRNewswire/ ... release of its latest report titled, "Continuous Glucose Monitoring ... - 2020". According to the report, the global continuous ... Mn in 2014 and is expected to reach US$ ... during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Sciences University, Augusta, GA  exhibited a poster ... Research in Los Angeles, in which their clinical study ... IV Connector significantly decreased the incidence of catheter-related ... to a simple split septum with negative displacement IV ...
... Food and Drug Administration is warning that terbutaline administered by ... in pregnant women for prevention or prolonged (beyond 48-72 hours) ... maternal heart problems and death. In addition, oral terbutaline tablets ... labor. The FDA is requiring the addition of a Boxed ...
Cached Medicine Technology:New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92% 2New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92% 3FDA Warns Against Certain Uses of Asthma Drug Terbutaline for Preterm Labor 2FDA Warns Against Certain Uses of Asthma Drug Terbutaline for Preterm Labor 3
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and alcohol ... North Conference Center. The medical community, social workers, law enforcement, and government officials ... aligned in the effort to better understand and combat sex trafficking. Lead by ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According to the article ... floor of the Pasadena courthouse was contained and extinguished by the city’s fire department before ... in the building at the time of the fire, and it was a fire alarm ...
(Date:7/31/2015)... Texas (PRWEB) , ... July 31, 2015 , ... As ... Sitter believes community involvement and support of animal welfare organizations is essential to the ... the third consecutive year in the National Association of Professional Pet Sitters (NAPPS) annual ...
(Date:7/31/2015)... ... 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State Health ... Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented a ... Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... FRIDAY, Jan. 14 (HealthDay News) -- Exposure to bright artificial ... your sleep and may increase the risk of high blood ... included 116 healthy participants, aged 18 to 30, who were ... eight hours before bedtime for five consecutive days. Blood plasma ...
... 2011) Based on a survey of thousands of ... physician-researchers from Los Angles Biomedical Research Institute at Harbor-UCLA ... a guide to the top 1 percent of physicians ... "America,s Top Doctors," chose another 16 LA BioMed physician-researchers ...
... Ont., Jan. 13, 2011Patients who must return to dialysis ... on home dialysis as hospital dialysis, but few choose ... Perl, a nephrologist at St. Michael,s Hospital. Despite ... an increasing number of patients return to dialysis. These ...
... study by Ohio State University cancer researchers provides a ... of targeted agents, one that inhibits an overactive, cancer-causing ... that silence genes that normally prevent cancer. Both types ... in clinical trials, the researchers note. The findings, published ...
... The more you walk, the lower your risk of diabetes, ... who participated in a study to map diabetes levels across ... at the start of the study and provided details about ... given a pedometer and instructed how to use it. ...
... 2011 AIUM Annual Convention and Preconvention Program, the only ... all disciplines of medical ultrasound, to be held April ... convention program incorporates an unprecedented selection of scientific research ... a focus on emerging applications and patient safety. ...
Cached Medicine News:Health News:Bright Lights at Night May Raise Diabetes Risk 2Health News:LA BioMed researchers among 'America's Top Doctors' 2Health News:Home dialysis effective for kidney patients after transplant fails 2Health News:Study provides molecular rationale for combining targeted agents to treat breast cancer 2Health News:The More You Walk, the Lower Your Diabetes Risk: Study 2Health News:AIUM unveils original features at 2011 convention 2
... stabilizer is an example of advanced technology ... the compression and comfort of a soft ... an ankle stirrup. A plastic exoskeleton ... fabric, forming a network of strategically placed ...
... with three regulated communicative chambers. It's one ... of low profile pneumatics to dramatically increase ... in other stirrups. The "slow rebound" air ... is enclosed and protected to prevent puncture. ...
... X-Brace is a cost effective stirrup designed to ... rehabilitation. It is lower in profile than other ... increasing potential patient compliance. The X-Brace offers the ... instep, and everts the foot. This allows the ...
... has a rigid shell with a vacuum liner ... The VacoSplint is a non-weight bearing splint. Once ... should transfer to the STORM walker boot., ... liner from the STORM and insert the vacuum ...
Medicine Products: